Medical devices provider DexCom (NASDAQ:DXCM) has launched its continuous glucose monitoring system DexCom G7 across the U.K., Ireland, Germany, Austria, and Hong Kong.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
DXCM also plans to introduce the product in New Zealand and South Africa in the coming weeks. The device sends real-time glucose data to a receiver without the need for finger sticks or scanning.
Further, the company is also working with insulin pump partners to integrate the device with present and future automatic insulin delivery systems.
Is DXCM Stock a Buy, Sell, or a Hold?
DXCM stock has gained nearly 11% over the past five days, and Wall Street sees a further 9.63% upside potential in the stock based on an average price target of $99.38 alongside a Strong Buy consensus rating.
The consensus rating for DXCM is based on 13 Buys and one Hold rating at present.
